In a counterclaim filed against Hanieh Sigari, Dariusz Banasik has revealed Qyral is “financially distressed”.

Banasik’s counterclaim was filed in addition to his April 20th filed answer to Sigari’s lawsuit.

Sigari
sued Banasik
last month, alleging she was “illegally locked out” of Qyral.

In his answer to Sigari’s Complaint, Banasik (right) denies the eight causes of action Sigari filed against him.

In his counterclaim, Banasik maintains he and Sigari “each own 50% of the membership interests in Qyral”.

In or around mid-2018, Counterclaimant and Sigari determined to launch a business marketing and selling skincare products.

Counterclaimant and Sigari formed Qyral in 2019, with its focus on selling skincare products.

Initially, things didn’t go so well.

From its inception, Qyral struggled with the sale of skincare products. From 2019 through 2022, the sale of the company were as follows:

•2019: $1,500

•2020: $45,000

•2021: $44,000

•2022: $64,000

“Prescription grade” skincare products were brought in as part of “certain industry changes in telehealth due to COVID-19”.

While sales picked up slightly, the fortunes of the company remained challenged.

As a consequence of the company’s struggles, and on behalf of Qyral, Counterclaimant requested, and, over time, obtained $1,300,000 in financing from Banabrands LLC dba ecomblvd (“Bananrands’), a company owned by Counterclaimant’s brother, Paul Banasik.

An additional infusion of $50,000 in financing from other family members was also made to Qyral.

By contrast, Sigari’s father funded $40,000, and was repaid at the end of 2023.

Qyral pivoted to “off-label” weight loss drugs in early 2023.

Counterclaimant convinced Sigari that in order to become cash flow positive, Qyral needed the weight loss product line, as it was not a sustainable business, absent a launch of its weight loss medication.

The introduction of off-label weight loss drugs saw Qyral generate $400,000 in revenue between March and April 2023. Banasik claims he was “intricately involved” in setting the transition up.

From May 2023, once the weight loss concept appeared viable, Counterclaimant and Sigari worked together to build out the infrastructure to get the product to customers, and include it as part of the Qyral product offering.

Sigari handled the physician network, sales team, and legal issues associated with medical products; Counterclaimant handled the pharmacy network, customer service, commission payments to consultants, and operations infrastructure.

With that structure, Qyral scaled the customer service team to 15 people in six months. Projected revenue for 2023 is forecasted to be 4,200,000, due in large part to Counterclaimant’s work.

Moreover, Counterclaimant structured a still pending Joint Venture agreement with an Arizona-based pharmacy that would “white label” its services, enabling Qyral to not only be a brand, but a pharmacy, further establishing Qyral’s legitimacy in the marketplace, as this woul

🤖 Quick Answer

What counterclaim did Dariusz Banasik file against Hanieh Sigari?
Banasik filed a counterclaim revealing that Qyral is "financially distressed." He maintains that both he and Sigari each own 50% of the membership interests in Qyral, which was formed in 2019 to market and sell skincare products after they determined to launch the business together around mid-2018.

What allegations did Hanieh Sigari make in her original lawsuit?
Sigari sued Banasik alleging she was "illegally locked out" of Qyral and filed eight causes of action against him. Banasik subsequently denied all eight causes of action in his answer filed on April 20th, while also submitting his counterclaim.

🔗 Related Articles

- Exp Realty dismissed from “drug & sexual assault” case
- Pruvit sues Vital Health for patent infringement
- SpinDing Review: $30 – $1890 cycler positions
- DFRF defendants ghost their attorneys, try to shirk SEC lawsuit
- Unetenet Global Review: Ponzi scheme launches third reboot